SynAct Pharma Logo

SynAct Pharma

SYNACT | ST

Overview

Corporate Details

ISIN(s):
SE0008241491 (+1 more)
LEI:
549300RRYIEFEQ72N546
Country:
Sweden
Address:
Scheelevägen 2, 223 63 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

SynAct Pharma is a clinical-stage biotechnology company focused on developing innovative medicines for inflammatory diseases. The company's core strategy centers on resolution therapy, an approach that aims to resolve, rather than inhibit, inflammatory processes by restoring the body's natural immune balance. Its lead candidate, resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development pipeline targets a wide spectrum of acute and chronic inflammatory conditions, such as rheumatoid arthritis, with the goal of reducing disease progression and offering a better-tolerated treatment alternative to establish a new standard of care.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for SynAct Pharma. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 07:30
Interim Report
Swedish 6.6 MB
2025-08-20 07:30
Interim Report
English 6.6 MB
2025-08-15 08:55
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter en andra konvertering av teckningsoptioner
Swedish 62.1 KB
2025-08-15 08:55
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after second conversion of warrants
English 61.3 KB
2025-08-05 11:34
Major Shareholding Notification
Swedish 10.6 KB
2025-07-31 18:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
Swedish 59.6 KB
2025-07-31 18:00
Share Issue/Capital Change
Change in number of shares and votes in SynAct Pharma AB
English 59.3 KB
2025-07-15 22:13
Share Issue/Capital Change
Correction: SynAct to receive SEK 17.7 million after conversion of warrants
English 61.8 KB
2025-07-15 22:13
Share Issue/Capital Change
Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
Swedish 62.8 KB
2025-07-15 21:00
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
Swedish 62.2 KB
2025-07-15 21:00
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after conversion of warrants
English 61.3 KB
2025-07-11 13:28
Major Shareholding Notification
Swedish 10.6 KB
2025-06-30 18:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
Swedish 59.0 KB
2025-06-30 18:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in SynAct Pharma AB
English 59.2 KB
2025-06-13 10:18
Major Shareholding Notification
Swedish 10.6 KB

Automate Your Workflow. Get a real-time feed of all SynAct Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SynAct Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-30 Anders Kronborg Other Buy 28,902 250,002.30 SEK
2024-06-01 Björn Westberg Other Other 516,205 N/A
2024-04-30 Jeppe Øvlesen Other Other 58,139 499,995.40 SEK
2024-04-30 Anders Kronborg Other Other 34,883 299,993.80 SEK
2024-03-21 Jeppe Øvlesen Other Other 245,870 1,696,503.00 SEK
2023-11-09 Thomas Jonassen Other Other 3,531,644 22,072,775.00 SEK
2023-11-09 Thomas Jonass Other Other 2,161,225 13,507,656.25 SEK
2023-01-16 Jeppe Øvlesen Other Other 1,161,777 72,727,240.20 SEK
2023-01-16 James Knight Other Other 77,452 4,848,495.20 SEK
2023-01-16 Thomas Boesen Other Other 32,917 2,060,604.20 SEK

Peer Companies

Company Country Ticker View
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden PILA
Plantarc Bio Ltd. Logo
Agritech firm using gene discovery & editing to improve crop yield, resilience, and pest control.
Israel PLNT
POLAREAN IMAGING PLC Logo United States of America POLX
Poltreg S.A. Logo
Develops T-regulatory cell (Treg) therapies for autoimmune diseases like diabetes and MS.
Poland PTG
POOLBEG PHARMA PLC Logo
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom POLB
Poxel Logo
Biopharma developing treatments for metabolic diseases like NASH, with a marketed drug for diabetes.
France POXEL
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom PRM
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom PXS
Psych Capital Plc Logo
Develops psilocybin-based therapies for anorexia nervosa and other mental health conditions.
United Kingdom PSY
Pure Biologics S.A. Logo
Develops novel antibody and aptamer drugs for immuno-oncology and autoimmunity.
Poland PUR